Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality.
Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient.
SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Frederiksborggade, 1,2.th.,denmark
- Phone
- +45 20 12 16 56
- tn****@****ino.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- synklino.com
- HQ
- Copenhagen, Capital Region of Denmark
Synklino Questions
Synklino's helpline number is +45 20 12 16 56
Synklino's website is synklino.com
Synklino's LinkedIn profile is https://dk.linkedin.com/company/synklino
Synklino has
13 employees.
View email and phone details for 13
employees at Synklino.
Synklino's industry is
Biotechnology Research
Synklino's top competitors are
Adcendo,
Hemab Therapeutics,
Hoba Therapeutics,
Bainan Biotech,
Muna Therapeutics,
Saniona,
Minervax Aps,
Evodiabio,
Io Biotech,
Acesion Pharma.
Synklino's support email address is tnk@synklino.com
Synklino's categories are Biotechnology Research
Synklino's founding year is 2017
